A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03141177 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

701

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: Nivolumab
DRUG: Cabozantinib
DRUG: Sunitinib
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]